Jeena Sikho Q1 FY27 Results (NSE: JSLL)
Signal: Margin expansion
The read
The trajectory remains strong: revenue grew 28.8% YoY to ₹22,440.48 lakh and EBITDA margin expanded to 47.4%, reversing the Q4FY26 36% level and extending the recent margin expansion arc; however, product-led growth is materially outpacing healthcare services and the ₹1,401.51 lakh other-income contribution warrants monitoring.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹224.4 Cr | +28.8% | +4.1% |
| EBIT | ₹91 Cr | +31.7% | |
| Net profit | ₹66.16 Cr | +27.8% | |
| EPS | ₹5.3 | +28.6% | |
| EBIT margin | 47.4% |
P&L walk
Consolidated revenue increased to ₹22,440.48 lakh, +28.8% YoY and +4.1% QoQ, led by products; EBITDA rose to ₹10,639 lakh with margin at 47.4%, while PAT reached ₹6,616.39 lakh, +27.8% YoY, supported partly by other income of ₹1,401.51 lakh.
Segments
Ayurvedic products drove the consolidated acceleration with revenue of ₹11,828.31 lakh, +47.8% YoY, and result of ₹4,124.11 lakh, +37.0%, while healthcare services grew revenue 11.1% YoY to ₹10,474.66 lakh but segment result slipped 0.4% to ₹4,271.13 lakh.
Key positives
- Ayurvedic-products revenue reached ₹11,828.31 lakh, +47.8% YoY, materially outpacing consolidated revenue growth of 28.8%.
- EBITDA margin expanded to 47.4%, up approximately 220bps YoY and 1120bps QoQ, following the 36% margin reported in Q4FY26.
- EPS rose 28.6% YoY to ₹5.30, slightly ahead of PAT growth of 27.8%, with no dilution signal from the PAT-to-EPS cross-check.
- Standalone PAT of ₹6,589.01 lakh was close to consolidated PAT of ₹6,616.39 lakh, indicating limited dependence on subsidiaries for current earnings.
Key concerns
- Healthcare-services segment result declined 0.4% YoY to ₹4,271.13 lakh despite 11.1% revenue growth, indicating weaker monetisation or cost absorption in the services business.
- Other income increased to ₹1,401.51 lakh from ₹106.85 lakh YoY and contributed meaningful support to PBT, even though the XBRL earnings-quality flag is clean.
- Finance costs rose 109.3% YoY to ₹347.35 lakh, which could become more significant as the company funds hospitals and international expansion.
Research and educational content only. Not investment advice.